Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome

Am J Obstet Gynecol. 2012 Mar;206(3):204.e1-5. doi: 10.1016/j.ajog.2011.12.035. Epub 2012 Jan 18.

Abstract

Objective: To evaluate long-term neurodevelopmental outcome of children treated with intrauterine transfusions for fetal anemia because of parvovirus B19 infection.

Study design: Children treated with intrauterine transfusions for fetal anemia because of parvovirus B19 infection underwent standardized age-appropriate neurodevelopmental testing. Main outcome was the incidence of neurodevelopmental impairment.

Results: Twenty-eight children were evaluated at a median age of 5 years (range, 1.5-13 years). Neurodevelopmental impairment was diagnosed in 3 of 28 (11%) children, including 1 child with combined cerebral palsy and severe developmental delay and 2 children with isolated severe developmental delay.

Conclusion: Neurodevelopmental impairment in children treated with intrauterine transfusion for parvovirus B19 infection is increased compared with the general population. Large long-term follow-up studies are required to determine potential risk factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Neonatal / therapy*
  • Anemia, Neonatal / virology
  • Blood Transfusion, Intrauterine / adverse effects*
  • Central Nervous System / growth & development*
  • Child
  • Child Development*
  • Child, Preschool
  • Developmental Disabilities / epidemiology*
  • Developmental Disabilities / etiology
  • Erythema Infectiosum / complications
  • Erythema Infectiosum / therapy*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Pregnancy
  • Pregnancy Complications, Infectious / therapy*
  • Treatment Outcome

Supplementary concepts

  • Parvovirus antenatal infection